Verona Pharma Plc, which develops medicines for respiratory diseases, has announced a share placement, subscription, and open offer with the intention of raising up to £14 million before expenses. The funds will be used to develop a compound for COPD.
Oxford Gene Technology Ltd, which provides equipment for genetics research, has acquired Cytocell Ltd, a Cambridge, UK-based supplier of probes for detecting DNA sequences called fluorescence in situ hybridisation or FISH. Financial terms were not disclosed.
Advanced Accelerator Applications SA, a French manufacturer of nuclear medicine products, is set to acquire Imaging Equipment Ltd, a privately-held UK distributor of nuclear medicine supplies, including products made by AAA.
Transgene SA, a French company specialising in oncolytic virus therapies, plans to raise €45.5 million with a partially underwritten equity offering on the Euronext Paris stock exchange. The company is offering 4,553,551 new ordinary shares at €10 per share.
Bavarian Nordic A/S has secured a new contract with an agency of the US government for its vaccine technology, this time with the Defense Threat Reduction Agency (DTRA), part of the Department of Defense.
Roche has entered into a collaboration with a two-year old UK company, Discuva Ltd, to discover and develop new antibiotics to treat infections caused by multi-drug resistant Gram-negative bacteria – the most difficult-to-treat bacteria.
Abingworth LLP has raised £225 million from investors for its tenth life sciences fund that will provide venture capital to companies in Europe and the US. The proceeds exceeded the investment group’s target of £200 million.
InDex Pharmaceuticals AB of Sweden has raised $20 million (€15 million) in a share placement with institutional investors ahead of the release of data from a late-stage trial of its lead product Kappaproct for severe ulcerative colitis.
Venture-capital backed Novimmune SA of Switzerland has secured CHF 60 million ($66 million) in new capital, its largest financing round in five years. The monies will be used to advance its pipeline of clinical-stage monoclonal antibodies.
Cellectis SA has reached an agreement with privately-owned Laboratoires Servier to develop and commercialise allogeneic T cell therapies for cancer. Under the agreement Servier will make an upfront payment of $10 million, and up to $140 million for each of six new products.